Drug class profile · refreshed daily from federal data

5-alpha Reductase Inhibitor

4 molecules in this class, $199.5M combined CY2024 Part D spend across 12.6M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the 5-alpha Reductase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
4tracked in Part D
CY24 Part D spend
$199.5Mcombined across class
Total Rx claims
12.6M4.0M unique beneficiaries
Generic mfrs (active)
22across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Finasteride
Brand: PROPECIA · 11.2M Part D claims (CY24) · 3.5M beneficiaries · First FDA approval:
9 generic mfrs 0 plans require PA Discontinued
Low NADAC$0.042
Avg plan cost$0.437
Part D spend $144.5M 10× spread, current vs floor
Class share
72%
of class CY24 spend
View profile →
02
Dutasteride
Brand: AVODART · 1.5M Part D claims (CY24) · 481K beneficiaries · First FDA approval:
10 generic mfrs 0 plans require PA
Low NADAC$0.168
Avg plan cost$0.169
Part D spend $55.0M spread, current vs floor
Class share
28%
of class CY24 spend
View profile →
03
Dutasteride and Tamsulosin
Brand: Jalyn · Part D claims (CY24) · First FDA approval:
3 generic mfrs 0 plans require PA
Low NADAC$2.05
Avg plan cost$2.05
Part D spend spread, current vs floor
Class share
0%
of class CY24 spend
View profile →